AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00193-08v1
52/6/1912    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ji, B.
Right arrow Articles by Jarlier, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ji, B.
Right arrow Articles by Jarlier, V.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2008, p. 1912-1916, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00193-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against Mycobacterium ulcerans in Mice {triangledown}

Baohong Ji,* Aurélie Chauffour, Jérome Robert, and Vincent Jarlier

Bactériologie-Hygiène, UPMC Universite Paris 06, EA 1541, F-75005, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, F-75651, Paris, France1

Received 11 February 2008/ Returned for modification 14 March 2008/ Accepted 24 March 2008

Treatment with rifampin-clarithromycin or moxifloxacin-clarithromycin for 8 weeks displayed promising bactericidal activity against Mycobacterium ulcerans in mice; none of the mice treated with rifampin-clarithromycin relapsed, whereas 59% of those treated with moxifloxacin-clarithromycin relapsed after treatment was stopped. The bactericidal and sterilizing activities of the five-times-weekly (5/7) administration of 5 mg of rifapentine/kg of body weight, either alone or in combination, were virtually identical to those of the corresponding regimens with 10 mg of rifampin/kg of body weight; however, because of the long half-life of rifapentine, accumulation of the drug after 5/7 administration is a concern. The bactericidal activity of 20 mg/kg rifapentine in monotherapy or 20 mg/kg rifapentine in combination with 150 mg/kg streptomycin or 200 mg/kg moxifloxacin administered twice weekly was as effective as the corresponding regimens containing 10 mg/kg rifampin administered 5/7, suggesting that Buruli ulcer might be treated with intermittently administered rifapentine-containing combinations.

* Corresponding author. Mailing address: Bactériologie-Hygiène, Faculté de Médecine Pierre et Marie Curie, Universite Paris 6, 91 boulevard de l'Hôpital, 75634 Paris Cedex 13, France. Phone: (331) 40 77 98 67. Fax: (331) 45 82 75 77. E-mail: baohong_ji{at}yahoo.com

{triangledown} Published ahead of print on 7 April 2008.

Antimicrobial Agents and Chemotherapy, June 2008, p. 1912-1916, Vol. 52, No. 6
0066-4804/08/$08.00+0     doi:10.1128/AAC.00193-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2008 by the American Society for Microbiology. All rights reserved.